Summary
Although the prognosis of high grade malignant glioma patients is generally poor, it is possible to identify groups of patients with varying prognoses. Basing our results on the first MRC glioma study, multivariate methods were used to identify prognostic factors independently associated with the length of survival. Young age, the presence of fits, especially of long duration, extensive surgical removal of tumour and good clinical performance status were found to be the most important predictors of longer survival. The effect of tumour grade (3 or 4) was not significant, being considerably diluted by an association with extent of neurosurgery. A prognostic index was derived which split the patients into 6 groups of varying prognoses, with 2-year survival rates of between 1 and 32%. The results were verified in patients entered into a subsequent MRC trial. The successful identification of different prognostic groups suggests the use of this index as an aid in making treatment decisions for individual patients, and in interpreting the results of uncontrolled phase II studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson AP: Post-operative irradiation of glioblastomas. Results in a randomised series. Acta Radiol 17: 475–484, 1978
Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Anderson AP, Elgen K: Combined modality therapy of operated astrocytomas grades III and IV. Confirmation of the value of post-operative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47: 649–652, 1981
Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosur 49: 333–343, 1978
Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomised comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303: 1323–1329, 1980
Kelly KA, Kirkwood JM, Kapp DS: Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev 11: 1–26, 1984
Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multi-disciplinary management of malignant gliomas. Cancer 52: 997–1007, 1983
EORTC brain tumour group: Evaluation of CCNU, VM-26 plus CCNU and procarbazine in supratentorial brain gliomas. J Neurosurg 55: 27–31, 1981
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batzdorf U, Brooks WH, Hunt WE, Mealey J, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR, Wilson CB, Strike TA: Comparison of carmustine, procarbazine and high-dose methyl-prednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121–132, 1983
MRC Working Party on Misonidazole in Gliomas: A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytoma. Br J Radiol 56: 673–682, 1983
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39, 1977
Cox DR: Regression models and life tables. J Roy Statist Soc, Ser B 34: 187–220, 1972
Kernohan JW, Sayre GP: Tumours of the central nervous system. In: Atlas of tumour pathology. Armed Forces Institute of Pathology, Washington DC, 1952 sec 10, fasc 35
Brisman R, Housepian EM, Chang C, Duffy P, Balis E: Adjuvant nitrosourea therapy for glioblastoma. Arch Neurol 33: 745–750, 1976
Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O'Bryan RM, McDonald B, Rivkin SE: Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. J Neuro-Oncol 1: 171–177, 1983
Gehan EA, Walker MD: Prognostic factors for patients with brain tumours. Nat Cancer Inst Monogr 46: 189–195, 1977
Byar DP, Green SB, Strike TA: Prognostic factors for malignant glioma. In: Walker MD, ed. Oncology of the nervous system. Martinus Nijhoff, Boston, 1983: 379–395
Nelson JS, Tsudaka Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas. Cancer 52: 550–554, 1983
Garrett MJ, Hughes HJ, Freedman LS: A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4: 71–76, 1978
Author information
Authors and Affiliations
Consortia
Additional information
This report was prepared on behalf of the participating members by S.P. Stenning, L.S. Freedman (statisticians) and N.M. Bleehen (Chairman). The following clinicians and their colleagues participated in the Misonidazole or BR2 studies and/or are members of the Brain Tumour Working Party: G.E. Adams, A.M.A. Ayoub Bey, R.O. Barnard, J. Bozzino, J.D. Bradshaw, T.B. Brewin, J. Bullimore, D.P. Dearnaley, P. Gortvai, N.F.C. Gowing, A. Gregor, J.M. Henk, H.F. Hope-Stone, A. Hovenden, N. Howard, H. Hughes, A. Jones, R.M. Kalbag, I. Kerby, V. Levin, A.R. Lyons, D.S. Murrell, M.J. Ostrowski, C.E. Polkey, R. Rampling, R.I. Rothwell, P.F. Salaman, C. Scholtz, J.S. Scott, R. Sealy, L.F.N. Senanayake, B. Southcott, J. Stone, H.M. Sultana, B.E. Tomlinson, C.S. Treip, S. Vaidya, P. Wale, P.J. Winter, P. Xavier. Data management was carried out by Mrs. Bethan Smith.
Rights and permissions
About this article
Cite this article
Medical Research Council. Prognostic factors for high-grade malignant glioma: Development of a prognostic index. J Neuro-Oncol 9, 47–55 (1990). https://doi.org/10.1007/BF00167068
Issue Date:
DOI: https://doi.org/10.1007/BF00167068